JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Grazoprevir hydrate (previously known as MK5172), the mono-hydrate form of grazoprevir, is a second generation, potent and selective inhibitor of the Hepatitis C Virus NS3/4A Protease with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively. Grazoprevir has been approved by FDA for the treatment of hepatitis C. It has a broad spectrum of activity across genotypes and resistant variants. Grazoprevir was originally developed by Merck with promising results in Phase II/III when used in combination with the NS5A replication complex inhibitor elbasvir, either with or without ribavirin. Grazoprevir acts at the NS3/4a protease sites with good activity against a range of HCV genotype variants, including some resistant variant that are resistant to most currently used antiviral drugs.
References: Antimicrob Agents Chemother. 2012 Aug; 56(8):4161-7; ACS Med Chem Lett. 2012 Mar 2; 3(4):332-6.
Related CAS#:350514-68-9 (free acid); 1206524-86-8 (potassium); 1425038-27-2 (sodium salt)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!